References
- Akgun E, Caliskan C, Celik HA, Ozutemiz AO, Tuncyurek M, Aydin HH. (2005). Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced experimental colitis in rats. J Int Med Res, 33, 196–206.
- Ardizzone S, Bianchi Porro G. (2005). Biologic therapy for inflammatory bowel disease. Drugs, 65, 2253–2286.
- Buege JA, Aust SD. (1978). Microsomal lipid peroxidation. Meth Enzymol, 52, 302–310.
- Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B, Buyukbese MA. (2005). Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med, 206, 131–139.
- Church DF, Pryor WA. (1985). Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect, 64, 111–126.
- Evans M, Laszlo R, Brendan J, Whitlle R. (2000). Site specific lesion formation inflammation and inducible nitric oxide synthase expression by indomethacin in the rat intestine. Eur J Pharm, 388, 281–285.
- Goel RK, Sairam K. (2002). Antiulcer drugs from indigenous sources with emphasis on Musasapientum tamrabhasma, Asparagus racemosus and Zingiber officinale. Indian J Pharmacol, 34, 100–110.
- Grzanna R, Lindmark L, Frondoza CG. (2005). Ginger-an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 8, 125–132.
- Kirtikar KR, Basu BD. (1956). Indian Medicinal Plants, second edition. Deharadun, Uttarakhand, India: International Book Distributors, 723.
- Krawisz JE, Sharon P, Stenson WF. (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology, 87, 1344–1350.
- Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. (2003). Intestinal oxidative damage in inflammatory bowel disease: Semi-quantification, localization, and association with mucosal antioxidants. J Pathol, 201, 28–36.
- Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM. (2003). Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett, 145, 79–87.
- Mohan H. (2005). Textbook of Pathology, fifth edition. New Delhi, India: Jaypee Brothers Medical Publishers, 580.
- Nadkarni AK. (1991). Indian Materia Medica, third edition. Bombay, Maharashtra, India: Bombay Popular Prakashan, 1197–1198.
- Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. (2006). Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol, 12, 4628–4635.
- Nakhai LA, Nakhai LA, Yasa N, Boushe VS. (2007). Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med, 4, 43–50.
- Otani T, Yamaguchi K, Scherl E, Du B, Tai H, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K, Dannenberg AJ. (2006). Levels of NAD+-dependent 15 hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: Evidence for involvement of TNF-α. Am J Physiol Gastrointest Liver Physiol, 290, G361–G368.
- Rutgeerts P, Geboes K. (2001). Understanding inflammatory bowel disease–the clinician’s perspective. Eur J Surg Suppl, 586, 66–72.
- Sands BE, Kaplan GG. (2007). The role of TNFalpha in ulcerative colitis. J Clin Pharmacol, 47, 930–941.
- Sartor RB. (1997). Pathogenesis and immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol, 92, 5S–11S.
- Stucchi A, Reed K, O’Brien M, Cerda S, Andrews C, Gower A, Bushell K, Amar S, Leeman S, Becker J. (2006). A new transcription factor that regulates TNFalpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflammatory Bowel Disease, 12, 581–587.
- Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. (1999). Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology, 46, 2338–2342.